Algorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening

MT Newswires Live

2025/05/08

Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.

The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.

The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533176539"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533176539\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533176539?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533176539","market":"nz","top_or_hot":-1,"title":"Algorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening","media":"MT Newswires Live","content":"<html><body><p> Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.</p><p>The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.</p><p>The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Algorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlgorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-08 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.</p><p>The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.</p><p>The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2533176539","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533176539","pubTimestamp":1746673130,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Algorae Pharmaceuticals  is working with the Victorian Center for Functional Genomics  at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","VCCTF":"Victoria","1AI.AU":"ALGORAE PHARMACEUTICALS LTD","BK4095":"家庭装饰品"},"translate_title":"Algorae Pharmaceuticals与维多利亚癌症中心合作进行药物协同筛选","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1AI.AU":0.9,"VCCTF":1},"content_text":"Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}